Stepan Co (SCL)

Reports for Stepan Co

Stepan Co
SCL
20-08-2025
Read Report
Stepan Co
SCL
10-07-2025
Read Report

Industries

Chemicals-Diversified
101001002
View Industry

Analysis

No analyses available for Stepan Co yet.

Latest News about Stepan Co

INVESTING
Nuvalent's SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock
1749855714 | INVESTING
NASDAQ
Genentech's Tecentriq & Lurbinectedin Show Positive Results In Phase III Trial For ES-SCLC
1748914809 | NASDAQ
NASDAQ
HCM : Phase III Study Of Savolitinib Combo Shows Promising Results For EGFR-Mutated NSCLC Treatment
1748834647 | NASDAQ
NASDAQ
HUTCHMED Reports Positive Results from SACHI Phase III Study of Savolitinib and Osimertinib in...
1748823026 | NASDAQ
Yahoo
Stepan Company (SCL): One of the Best Dividend Kings to Buy for Safe Dividend Growth
1743944178 | Yahoo
INVESTING
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1...
1735470243 | INVESTING
NASDAQ
How The Parts Add Up: USCL Targets $79
1735047285 | NASDAQ
NASDAQ
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
1734441660 | NASDAQ
NASDAQ
FDA Grants Accelerated Approval For Merus' BIZENGRI For Pancreatic Adenocarcinoma And NSCLC
1733368611 | NASDAQ
INVESTING
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant...
1733289124 | INVESTING
NASDAQ
Zai Lab's AUGTYRO For ROS1+ NSCLC Added To China's National Reimbursement Drug List
1732772711 | NASDAQ
INVESTING
Zai Lab Announces the Inclusion of AUGTYRO ® (repotrectinib) for ROS1+ NSCLC and Other Updates...
1732766883 | INVESTING
NASDAQ
SCL Breaks Above 2% Yield Territory
1732654743 | NASDAQ
INVESTING
SCLX stock touches 52-week low at $0.54 amid market challenges
1732286336 | INVESTING
NASDAQ
Monday's ETF Movers: URA, USCL
1731950964 | NASDAQ
NASDAQ
Surprising Analyst 12-Month Target For USCL
1731932768 | NASDAQ
INVESTING
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
1722245765 | INVESTING
INVESTING
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449...
1717301284 | INVESTING
INVESTING
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly ® (sugemalimab,...
1717288084 | INVESTING
INVESTING
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily...
1717261923 | INVESTING
INVESTING
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based...
1717240804 | INVESTING
INVESTING
 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC...
1717197124 | INVESTING
INVESTING
Pfizer's LORBRENA shows sustained NSCLC patient benefit over five years
1717178434 | INVESTING
INVESTING
Ivonescimab shows promise in NSCLC Phase III trial
1717095159 | INVESTING
INVESTING
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves...
1717093924 | INVESTING
YAHOO
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
1715614932 | YAHOO
INVESTING
Janux Therapeutics sharestarget raised by H.C. Wainwright on NSCLC data
1715601036 | INVESTING
INVESTING
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by...
1715560325 | INVESTING
FPOST
MARKSMEN ANNOUNCES FILING OF ITS ANNUAL DISCLOSURE DOCUMENTS ON SEDAR+
1714438300 | FPOST